Anika Therapeutics, Inc. — Operating Income by Fiscal Year
17 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/fe9c021c-62fa-4470-84fe-5234a1fc4b02/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-11.1M | 2025-01-01 – 2025-12-31 | evidence 0001171843-26-001275 |
| FY 2024 | $-5.1M | 2024-01-01 – 2024-12-31 | evidence 0001171843-25-001486 |
| FY 2023 | $844.0k | 2023-01-01 – 2023-12-31 | evidence 0001171843-25-001486 |
| FY 2022 | $3.7M | 2022-01-01 – 2022-12-31 | evidence 0001171843-25-001486 |
| FY 2021 | $2.6M | 2021-01-01 – 2021-12-31 | evidence 0001171843-22-001790 |
| FY 2020 | $-28.3M | 2020-01-01 – 2020-12-31 | evidence 0001171843-21-001573 |
| FY 2019 | $34.2M | 2019-01-01 – 2019-12-31 | evidence 0001171843-20-001536 |
| FY 2018 | $21.7M | 2018-01-01 – 2018-12-31 | evidence 0001171843-19-001243 |
| FY 2017 | $45.7M | 2017-01-01 – 2017-12-31 | evidence 0001171843-18-001450 |
| FY 2016 | $50.6M | 2016-01-01 – 2016-12-31 | evidence 0001171843-17-001121 |
| FY 2015 | $48.1M | 2015-01-01 – 2015-12-31 | evidence 0001171843-16-008487 |
| FY 2014 | $61.4M | 2014-01-01 – 2014-12-31 | evidence 0001171843-16-008487 |
| FY 2013 | $32.6M | 2013-01-01 – 2013-12-31 | evidence 0001171843-16-008487 |
| FY 2012 | $19.7M | 2012-01-01 – 2012-12-31 | evidence 0001157523-13-001397 |
| FY 2011 | $14.0M | 2011-01-01 – 2011-12-31 | evidence 0001157523-12-001365 |
| FY 2010 | $7.5M | 2010-01-01 – 2010-12-31 | evidence 0001157523-12-001365 |
| FY 2009 | $5.6M | 2009-01-01 – 2009-12-31 | evidence 0001157523-12-001365 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).